Expert Interview
A Second View: Reviewing the current treatment landscape for macular edema, with a focused look at Kodiak Sciences recent phase 3 data on Tarcocimab
Ticker(s): KOD, REGNInstitution: Duke
- Vitreoretinal Surgeon, Professor of Ophthalmology & Associate Professor of Surgery at Duke University School of Medicine, Associate Chief of Staff, Durham VA Health System and Co-Director of Duke Neurodegenerative Disease Retinal Imaging Repository.
- Manages 200 patients/month with Macular Edema & 250 patients (total) with Geographic Atrophy.
- Co-authored over 150 publications in peer-reviewed medical journals and over 50 textbook chapters; Leads an international multidisciplinary clinical research team evaluating multimodal retinal and optic nerve imaging for the diagnosis of Alzheimer's disease and other neurodegenerations.
Please describe your background and practice setting
Added By: ben_adminHow many patients with Macular Edema do you treat monthly?
Added By: ben_adminWhat are your thoughts on the recent phase 3 data from Kodiak Science?
Added By: ben_adminCan you rate your excitement for Tarcocimab on a scale of 1-10?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
